Newsfile Corp
23 Jun 2026, 00:37 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ADMA Biologics is accused of using channel stuffing to report 20% revenue growth in 2025 when actual growth was allegedly -3%. — Allegations of systemic revenue fabrication and growth misrepresentation are fundamental drivers of stock devaluation and loss of investor trust.
-0.90A federal securities class action lawsuit has been filed against ADMA Biologics alleging violations of federal securities laws. — Class action litigation creates significant legal liability and potential financial settlements that weigh on company valuation.
-0.60The company is alleged to have engaged in undisclosed related party transactions and lacked adequate internal controls. — Poor internal controls and undisclosed conflicts of interest suggest systemic governance failures and increase the risk of further accounting surprises.
-0.50Which stocks this story touches
Continue reading
6 related stories
Search tags
The company is facing a federal securities class action lawsuit alleging fraud, channel stuffing, and misleading financial statements.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
Newsfile Corp
5h ago
